Plain-English translation of NCT07584954 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This Phase I trial is testing a new medication called IUAb190708, which is a type of antibody designed to fight cancer by activating immune cells called NK cells to directly attack tumor cells. Unlike some other cancer immunotherapies that work indirectly, this medication is designed to trigger a more direct immune response against the tumor. Researchers want to find the safest and most effective dose of this treatment in people with advanced or recurrent solid tumors.
Many patients with advanced cancers do not respond to available treatments or cannot receive standard therapy. This medication uses a different approach to boost the immune system against cancer, and early research suggests it may help when combined with other treatments or used on its own.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
After a 28-day screening period, you will receive intravenous infusions of the medication every 2 weeks at one of several dose levels. The study starts with lower doses and gradually increases the dose in different groups of participants to find the safest level. Researchers will closely monitor your health through blood tests, imaging scans, and clinic visits to track how your body responds and whether your tumors shrink. The exact length of treatment will depend on how well you tolerate the medication and how your cancer responds.
AI-generated summary from trial data ยท Sep 4, 2026 ยท Not medical advice
China